Abtrax Pharmaceuticals, Inc. v. Elkins-Sinn, Inc.

655 A.2d 1368, 139 N.J. 499, 1995 N.J. LEXIS 48
CourtSupreme Court of New Jersey
DecidedApril 10, 1995
StatusPublished
Cited by136 cases

This text of 655 A.2d 1368 (Abtrax Pharmaceuticals, Inc. v. Elkins-Sinn, Inc.) is published on Counsel Stack Legal Research, covering Supreme Court of New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Abtrax Pharmaceuticals, Inc. v. Elkins-Sinn, Inc., 655 A.2d 1368, 139 N.J. 499, 1995 N.J. LEXIS 48 (N.J. 1995).

Opinion

The opinion of the Court was delivered by

STEIN, J.

The issue before us is whether a complaint should be dismissed pursuant to Bule 4:23-2(b)(3) for discovery misconduct consisting of the willful concealment of relevant documents. The Law Division found that plaintiffs conduct was contumacious, dismissed plaintiffs complaint with prejudice, and awarded counsel fees and expenses. In an unreported opinion, the Appellate Division agreed with the finding that plaintiff had willfully concealed relevant documents, affirmed the award of counsel fees and expenses, but reversed the trial court’s dismissal of the complaint. We granted certification, 137 N.J. 314, 645 A.2d 142 (1994), and now hold that the trial court properly exercised its discretion in dismissing Abtrax’s complaint. As a result, we reverse in part the judgment of the Appellate Division and reinstate the judgment of the Law Division dismissing the complaint.

I

Plaintiff Abtrax Pharmaceuticals, Inc., (Abtrax) is a wholesaler of veterinary supplies located in Navesink, New Jersey. Charles *503 W. Rahner, Jr., the company’s president, owns ninety-nine percent of Abtrax’s stock'. In August 1969, defendant, Elkins-Sinn, Inc. (Elkins), agreed to package a veterinary product developed by Abtrax called Gecolate, an intravenous muscle relaxant for horses. Rahner and Elkins developed techniques for sterilizing the Gecolate powder and packaging it so that sterile water could be added before use. Abtrax holds the patent for that process. Production began in 1972 when the Food and Drug Administration approved Abtrax’s New Animal Drug Application. By 1974, Abtrax began marketing the product.

In February 1982, Elkins informed Abtrax that it would stop producing Gecolate powder. In 1984, A.H. Robins, which became Elkins’s parent company after the initial production of Gecolate powder, began to market Guailaxin, a competing product. Although Rahner claims that he was unsuccessful in finding an alternative manufacturer, since 1987 Vet Labs, Inc. has been producing Gecolate injection for Abtrax, a solution form of the product that Abtrax bought from another company.

In December 1985, Abtrax filed a three-count complaint alleging that Elkins had breached its contract by ceasing to manufacture Gecolate powder without sufficient notice to permit Abtrax to find a new manufacturer (counts one and two). Abtrax further alleged that Elkins had revealed trade secrets to competing manufacturers (count three). Elkins filed an answer and requested production of documents relating to Abtrax’s claims. In April 1986, Abtrax responded to Elkins’s request by stating, “we have not yet been able to do an accurate calculation of damages although the same will be supplied to you as soon as it is available to us.”

After repeated efforts to obtain answers to interrogatories and production of documents relating to Abtrax’s alleged damages, Elkins received answers to its interrogatories in November 1986. However, in respect of Elkins’s request for copies of correspondence concerning Abtrax’s attempts to find other manufacturing sources, Abtrax responded: “to be supplied.” Abtrax did not produce the documents that Elkins had requested. After further requests for the production of the documents had proved unavailing, Elkins moved pursuant to Rule 4:23-5(a) to dismiss Abtrax’s *504 complaint because timely answers to interrogatories had not been served.

The Law Division denied Elkins’s motion, but permitted Elkins’s counsel to inspect the requested documents at Abtrax’s office. At a discovery session for document production held on February 25, 1987, Abtrax made available inventory sheets, price lists, raw-material costs, and a summary of taxable income, but Abtrax did not produce purchase orders, sales invoices, tax returns, and financial statements. Elkins’s counsel certified that Abtrax’s former counsel had “advised [him during the document production] that Mr. Rahner did not have sales invoices or purchase orders concerning the Geeolate powder insofar as [they] were either lost or destroyed in a flood at Plaintiffs business premises sometime earlier,” noting, however, that Abtrax’s former counsel “did agree to make further inquiry into this and provide me * * * with at least representative invoices or whatever additional records could be found.” However, Abtrax’s former counsel, at his deposition in February 1991, testified:

I don’t think I made a statement to that effect. * * * It’s possible that something like that was discussed. I believe there may have been a discussion about a flood or records being discussed * * *. [Rahner] may have said there was a destruction of the sales invoices, but not that they were all destroyed.

Moreover, according to Abtrax’s former counsel, Elkins’s counsel had stated at that document-production session that those documents Abtrax had produced were “exactly what I wanted.” Shortly after the February 25, 1987, production of documents, Elkins’s counsel requested by letter that Rahner bring to his deposition scheduled for March 10, 1987, “[representative copies of billing receipts to [Gecolate-powder] customers 1980, 1981, and 1982, or as best as can be produced.” Prior to being deposed, Rahner produced certain financial records, correspondence, inventory sheets, invoices, and purchase orders. At his deposition, Rahner was asked whether he had “produced * * * everything [he had] in the matter,” and he responded, “Yes.” On further questioning, Rahner stated that he had “[produced everything that was requested.” However, Rahner produced copies of the billing receipts of Gecolate-powder sales only for the years 1982 *505 through 1984, whereas Elkins had specifically requested production of the records for the period 1980 through 1982.

In May 1987, Abtrax moved to file an amended complaint to add two counts alleging (1) that Elkins had breached an agreement regarding the use of Abtrax’s powder-filling machine, and (2) that Elkins had converted the machine for its own use and the use of its parent company, A.H. Robins. Because that motion had been denied, Abtrax jiled a new complaint in June 1987, repeating the three counts in its initial complaint and adding the new counts. By order dated August 14, 1987, the court dismissed without prejudice the original complaint and ordered all completed discovery to be applied to the action initiated by the new complaint.

As the discovery process continued, Elkins attempted to acquire the invoices and purchase orders relevant to Abtrax’s sales of Gecolate powder from 1980 to 1982, the years immediately prior to the termination of the agreement between the parties, as well as invoices for all other years through 1986. In February 1988, Elkins filed a notice to produce “[a]ll records, writing, documents, items or other documentation as identified and requested in Defendant’s Interrogatories.” Elkins’s interrogatory question fifty-five read, “State whether you have any files or written documentation whatsoever in any way relating to this law suit [that] you have not produced previously for * * * inspection [and/or] copying.” Abtrax responded, “Not to the best of our knowledge.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Frank Castella v. Gerald J. Lepis, Esq.
New Jersey Superior Court App Division, 2025
Fang Liu v. Affinity Care of Nj
New Jersey Superior Court App Division, 2025
Jean-Philippe Diero v. Eric S. Kim
New Jersey Superior Court App Division, 2025
Agostino & Associates, P.C. v. J. Rapaport Wood Flooring LLC
New Jersey Superior Court App Division, 2025
Chryssoula Arsenis v. Edward Frank
New Jersey Superior Court App Division, 2024
Eil Investments, Lp v. Steven E. Angstreich
New Jersey Superior Court App Division, 2024
Christian Gonzales v. Wilfredo Mejia-Mendoza
New Jersey Superior Court App Division, 2024
Lourdy Jordonne v. Lucien Saint Louis
New Jersey Superior Court App Division, 2024
Jacqueline Wynn v. Germaine N. Johnson
New Jersey Superior Court App Division, 2024
Steven Anello v. Mark J. Ingber, Esq.
New Jersey Superior Court App Division, 2024
North Jersey Hip and Knee Center v. Janet Quevedo
New Jersey Superior Court App Division, 2024
Siria Hernandez and Felix Pereyra v. La Fortaleza, Inc.
New Jersey Superior Court App Division, 2024
Seaside Properties, LLC v. Arf Realty Management
New Jersey Superior Court App Division, 2023
A.M.S. VS. M.L.S. (FM-12-1279-17, MIDDLESEX COUNTY AND STATEWIDE)
New Jersey Superior Court App Division, 2021

Cite This Page — Counsel Stack

Bluebook (online)
655 A.2d 1368, 139 N.J. 499, 1995 N.J. LEXIS 48, Counsel Stack Legal Research, https://law.counselstack.com/opinion/abtrax-pharmaceuticals-inc-v-elkins-sinn-inc-nj-1995.